Figure 1. – General distribution of the serum levels of sOSMR and sgp130 of the study population. A) Serum levels of sOSMR (soluble oncostatin M receptor) in pg / mL in the control subjects (CT) and the groups chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). B) Serum levels of sgp130 (soluble glycoprotein 130) in pg / mL in the CT and the groups chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). ****p <0.0001 vs control: Significant after analysis Kruskal-Wallis test.